Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Ashley Marton, M.D.C.M., Joins The Eugene M. and Christine E. Lynn Cancer Institute as a Hematologist and Medical Oncologist
Hematologist and medical oncologist Ashley Marton, M.D.C.M., has joined the Eugene M. and Christine E. Lynn Cancer Institute - Boynton Beach, part of Baptist Health Cancer Care
Clinical Scorecard: Ashley Marton, M.D.C.M., Joins The Eugene M. and Christine E. Lynn Cancer Institute as a Hematologist and Medical Oncologist
At a Glance
Category
Detail
Condition
Solid tumors and hematologic conditions; clinical focus on breast, prostate and colon cancers
Key Mechanisms
Not described in the source
Target Population
Patients treated by Dr. Marton for solid tumors or hematologic conditions
Care Setting
Lynn Cancer Institute, Boynton Beach, Florida, part of Baptist Health Cancer Care
Key Highlights
Ashley Marton, M.D.C.M., joined Lynn Cancer Institute as a hematologist and medical oncologist.
Her clinical focus includes breast, prostate and colon cancers, alongside a broad range of solid tumors and hematologic conditions.
She has served as a principal investigator and sub-investigator in oncology clinical trials.
Her care philosophy emphasizes collaboration, patient education and shared decision-making.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients treated by Dr. Marton for solid tumors or hematologic conditions at Lynn Cancer Institute.
The source provides no medication or prescribing details. It states that Dr. Marton develops evidence-based, individualized treatment plans and is interested in integrating new cancer treatments into care.
Clinical Best Practices
Dr. Marton describes her care philosophy as rooted in collaboration, patient education and shared decision-making.
She says she aligns clinical evidence with patients’ personal values, lifestyle and individual goals.
The source states that she has served as a principal investigator and sub-investigator in oncology clinical trials.